TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37852530
Drug: Recommended Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended Treatment of Obesity in Primary Care (RTOP)
Study: 37852737
Drug: Nivolumab (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (480 mg) and metformin (1000 mg, orally, twice daily after a 14-day lead-in phase)
Study: 37852774
Drug: MyCog paradigm
Normalized name: Mycogone nigra
DrugBank: Mycogone nigra (DB10971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyCog paradigm (iPad-based, self-administered cognitive assessment)
Study: 37853118
Drug: Oncolytic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncolytic immunotherapy
Study: 37853420
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (extracorporeal shockwave therapy + myofascial release therapy)
Study: 37853454
Drug: H3K27M-vac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3K27M-vac vaccine administered with standard radiotherapy (RT) and atezolizumab (ATE)
Study: 37853490
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein dose (≥ 2.2 g/kg body weight/day)
Study: 37853490
Drug: Usual protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual protein dose (≤ 1.2 g/kg body weight/day)
Study: 37853605
Drug: Intensive adherence
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive adherence counselling (IAC) - three once-monthly sessions
Study: 37853676
Drug: 0.002% omidenepag
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.002% omidenepag isopropyl (OMDI) once daily in both eyes for 3 months
Study: 37855022
Drug: High-dose multimatrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multimatrix mesalamine (1800-4800 mg)
Study: 37855022
Drug: Low-dose multimatrix
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multimatrix mesalamine (900-2400 mg)
Study: 37855026
Drug: Inhaled interferon-β1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled interferon-β1a (SNG001) given once daily for 14 days
Study: 37855227
Drug: Shortened course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened course of antibiotics
Study: 37855227
Drug: Standard course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard course of antibiotics
Study: 37855277
Drug: Online storytelling-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online storytelling-based acceptance and commitment therapy (ACT)
Study: 37855448
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg subcutaneous injections monthly for 80 weeks)
Study: 37856013
Drug: Alfosbuvir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfosbuvir plus Daclatasvir (600 mg alfosbuvir + 60 mg daclatasvir once daily for 12 weeks)
Study: 37856106
Drug: Capecitabine (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (625 mg/m2 orally twice daily for 21 days), Oxaliplatin (130 mg/m2 intravenously), Pembrolizumab (200 mg intravenously), with optional Epirubicin (50 mg/m2 every 3 weeks); followed by maintenance Pembrolizumab (14 additional doses).
Study: 37856173
Drug: Sense2Quit App
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sense2Quit App with 8-week supply of nicotine replacement therapy, standard smoking cessation counseling, and access to the Sense2Quit mobile app and smartwatch
Study: 37856182
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group A (treatment as usual)
Study: 37856182
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group B (treatment as usual)
Study: 37856199
Drug: VEGFR TKI
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGFR TKI therapy
Study: 37856212
Drug: Maximal tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal tumor debulking followed by systemic therapy
Study: 37856386
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted hybrid version of the Incredible Years School Age Basic and Advance Programs delivered online, 12 weekly 2-hr sessions.
Study: 37856920
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg ARA and 50 mg/kg DHA supplementation
Study: 37857068
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion of 500 mL of crystalloid solution
Study: 37857147
Drug: Differential expression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differential expression of piRNAs in patients with hormonal treatment
Study: 37857168
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 20 mg/kg after induction (n=300)
Study: 37857496
Drug: Reduced HR
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced HR augmentation in OH participants
Study: 37857528
Drug: Ociperlimab 1800
Normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ociperlimab 1800 mg plus Tislelizumab 200 mg Q3W
Study: 37857528
Drug: Ociperlimab 900
Normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ociperlimab 900 mg plus Tislelizumab 200 mg Q3W
Study: 37857528
Drug: Ociperlimab 450
Normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ociperlimab 450 mg, 900 mg, and 1800 mg
Study: 37857620
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg ketamine
Study: 37857710
Drug: Resistant potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant potato starch (RPS) daily from day -7 to day 100
Study: 37857711
Drug: Tebotelimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebotelimab monotherapy (600 mg once every 2 weeks)
Study: 37857711
Drug: Tebotelimab in
Normalized name: Tebotelimab
DrugBank: Tebotelimab (DB16685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebotelimab in combination with margetuximab
Study: 37857939
Drug: TXA administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA administered at the beginning of induction (TXAI)
Study: 37857939
Drug: TXA administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA administered at the end of surgery (TXAP)
Study: 37858005
Drug: Daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 50 mg once daily
Study: 37858007
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg Q4W
Study: 37858007
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg Q2W
Study: 37858132
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for OMD
Study: 37858212
Drug: RPP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPP group (low-dose and low-concentration iodine contrast medium)
Study: 37858247
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) supplementation, 4 IU/day subcutaneous from the beginning of ovarian stimulation (OS) to the trigger day.
Study: 37858262
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) components
Study: 37858328
Drug: Emicizumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab (6 and 3 mg/kg on days 1 and 2, 1·5 mg/kg weekly until week 12)
Study: 37858585
Drug: Ad26.ZEBOV followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV followed by MVA-BN-Filo (Ebola vaccine group)
Study: 37858585
Drug: Meningococcal quadrivalent
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal quadrivalent conjugate vaccine (control group)
Study: 37858724
Drug: Maternal supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal supplement use during pregnancy
Study: 37858867
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy after 3-5 days of IV therapy
Study: 37859647
Drug: Narrow band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow band green light (NbGL) treatment during migraine attacks
Study: 37859748
Drug: Medium-dose ahaMSCs-Exos
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ahaMSCs-Exos (intranasally administered two times per week for 12 weeks)
Study: 37860863
Drug: Evinacumab 15
Normalized name: evinacumab 150 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Evkeeza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evinacumab 15 mg/kg every 4 weeks
Study: 37861218
Drug: Tarlatamab 10
Normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarlatamab 10 mg every 2 weeks
Study: 37861218
Drug: Tarlatamab 100
Normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarlatamab 100 mg every 2 weeks
Study: 37861407
Drug: AGS15E at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGS15E at 1.00 mg/kg
Study: 37861407
Drug: AGS15E at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGS15E at doses of ≥0.75 mg/kg
Study: 37861407
Drug: AGS15E at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGS15E at doses of 0.50 to 1.25 mg/kg
Study: 37861675
Drug: HBV active
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV active drugs (HBV-ARV)
Study: 37861988
Drug: Computer-Assisted Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-Assisted Cognitive Behavioral Therapy
Study: 37862013
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and Velpatasvir 100 mg for 12 weeks (2-week starter pack provided at diagnosis)
Study: 37862013
Drug: Sofosbuvir-velpatasvir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir treatment
Study: 37862823
Drug: Oral omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omega-3 fatty acids capsules (1 g daily)
Study: 37862832
Drug: CANKADO-inform arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CANKADO-inform arm (drug intake documentation only)
Study: 37863080
Drug: Rusfertide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rusfertide (10 mg once weekly for 24 weeks)
Study: 37863084
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous insulin icodec
Study: 37863158
Drug: Standard opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid prescription protocol (3-10 tablets of 5 mg oxycodone upon discharge)
Study: 37863158
Drug: Restrictive opioid
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive opioid prescription protocol (no opioid prescription unless requested)
Study: 37863158
Drug: Standard opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid prescription protocol
Study: 37863158
Drug: Restrictive opioid
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive opioid prescription protocol
Study: 37863195
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg intrathecal morphine
Study: 37863195
Drug: 150 mcg
Normalized name: kelp 150 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mcg intrathecal morphine
Study: 37863195
Drug: 250 mcg
Normalized name: Nplate 250 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg intrathecal morphine
Study: 37863418
Drug: Oxygen reserve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen reserve index-guided oxygen titration
Study: 37863418
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen titration based on pulse oximetry
Study: 37863878
Drug: Laparoscopic TME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic TME with Denonvilliers' fascia preservation (L-DVF-P)
Study: 37863878
Drug: Laparoscopic TME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic TME with Denonvilliers' fascia resection (L-DVF-R)
Study: 37863916
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg on day 1) plus nab-paclitaxel (125 mg/m2) and epirubicin (dosage not specified)
Study: 37864049
Drug: Nimotuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab plus concurrent chemo-radiotherapy (CCRT)
Study: 37864049
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus concurrent chemo-radiotherapy (CCRT)
Study: 37864152
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiation therapy (SABR) in addition to standard of care (Arm 2)
Study: 37864152
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy (Arm 1)
Study: 37864252
Drug: Immersive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive virtual reality (VR) therapy through an immersive VR garden intervention
Study: 37864252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional post-stroke rehabilitation program without VR therapy)
Study: 37864281
Drug: Lisinopril (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (0.05 to 0.2 mg/kg, oral, once daily in the morning)
Study: 37864379
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: insulin glargine (IGlar)
Study: 37864379
Drug: beinaglutide combined
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: beinaglutide combined with insulin glargine (IGlar)
Study: 37864583
Drug: Nutritional stabilization
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional stabilization and medical treatment during hospitalization (mean hospitalization: 6 weeks)
Study: 37864596
Drug: Lifestyle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle therapy (Control)
Study: 37864646
Drug: PT2385 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT2385 (800 mg b.i.d.)
Study: 37864885
Drug: 4-(3-1H-indazolyl)amino quinazoline
Normalized name: 4-amino-PGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-(3-1H-indazolyl)amino quinazoline derivatives (compounds 27e, 27g, 27i, and 27j)
Study: 37865043
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg vaccine
Study: 37865043
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg vaccine
Study: 37865043
Drug: 45 μg
Normalized name: tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 μg vaccine
Study: 37865043
Drug: One 45
Normalized name: idebenone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 45 μg dose of vaccine followed by placebo (Part 1 only)
Study: 37865048
Drug: Nimotuzumab (NTZ)
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (NTZ) combined with concurrent chemoradiotherapy (CCRT)
Study: 37865138
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) 380 mg/month
Study: 37865138
Drug: Buprenorphine-naloxone (BP-NLX)
Normalized name: buprenorphine / naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone (BP-NLX) 8-24/2-6 mg daily
Study: 37865397
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg) and tremelimumab (75 mg) with neoadjuvant chemotherapy (NAC) for three cycles, followed by interval debulking surgery (IDS), then durvalumab (1120 mg) and adjuvant chemotherapy for three cycles, followed by durvalumab maintenance (1120 mg for total 12 cycles).
Study: 37865397
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) combined with durvalumab and tremelimumab.
Study: 37865397
Drug: Treatment-related adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related adverse events (TRAEs) from durvalumab and tremelimumab.
Study: 37865101
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg once daily for 28 days
Study: 37865736
Drug: Surf tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surf tablet usage
Study: 37865736
Drug: Surf tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surf tablet usage among satisfied parents
Study: 37865771
Drug: Pegunigalsidase alfa
Normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegunigalsidase alfa (1 mg/kg every 2 weeks)
Study: 37865771
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa (0.2 mg/kg every 2 weeks)
Study: 37865776
Drug: Pre-ICI collections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ICI collections from patients with irAEs G ≥ 2
Study: 37865776
Drug: Post-treatment collections
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment collections from subjects experiencing irAEs G ≥ 2
Study: 37865776
Drug: Post-treatment collections
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment collections after steroids
Study: 37865807
Drug: COMORAL (multi-channeled
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMORAL (multi-channeled oral irrigation unit) used 3 times a day, 5 days a week
Study: 37865807
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplementary oral hygiene products, brushing 1-2 times a day)
Study: 37865807
Drug: COMORAL (multi-channeled
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMORAL (multi-channeled oral irrigation unit)
Study: 37865896
Drug: Lazertinib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib (240 mg/d)
Study: 37866442
Drug: Cycle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle of trauma and drug use exacerbated by oppression in substance use services settings
Study: 37866460
Drug: Remibrutinib 100
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remibrutinib 100 mg twice daily for 52 weeks
Study: 37866669
Drug: Autologous hematopoietic
Normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous hematopoietic stem cell transplantation (aHSCT) with cyclophosphamide 200 mg/Kg and rituximab 1000 mg
Study: 37867420
Drug: Perampanel 4
Normalized name: perampanel 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 4 mg/day
Study: 37868294
Drug: Lacalut cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacalut cleaning tablet
Study: 37868294
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brushing and Lacalut cleaning tablet
Study: 37868649
Drug: Acthar Gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar Gel
Study: 38416237
Drug: Faricimab treatment
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faricimab treatment
Study: 37868959
Drug: Plasma biomarkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma biomarkers (endothelin-1, von Willebrand factor, Interleukin-1 Receptor antagonist)
Study: 37869085
Drug: Regorafenib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (80 mg once daily on days 1-21 of each 28 days cycle) + Toripalimab (240 mg, q3w) + High-dose radiotherapy (4-8 fractions of 8-12Gy) and Low-dose radiotherapy (1-10Gy at 0.5-2Gy/fraction)
Study: 37869085
Drug: Regorafenib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (120 mg once daily on days 1-21 of each 28 days cycle)
Study: 37869139
Drug: Vertigoheel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertigoheel treatment for 2 months
Study: 37869360
Drug: Rilzabrutinib 400
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib 400 mg BID
Study: 37870130
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (various types including penicillins, cephalosporins, macrolides, and trimethoprim) for 10-14 days
Study: 37870163
Drug: SB16 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB16 (60 mg dose)
Study: 37870163
Drug: EU-DEN (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-DEN (60 mg dose)
Study: 37870163
Drug: US-DEN (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-DEN (60 mg dose)
Study: 37870228
Drug: PB-IORT (Precision
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy delivering 12.5 Gy to the tumor bed.